This Los Angeles Lymphoma Rounds will now be a virtual program to deliver live professional education programming during the coronavirus (COVID-19) outbreak. This program will still provide a forum for local practicing physicians from academic and community medical centers to meet and address issues specific to the diagnosis and treatment of their lymphoma patients. You will be able to tune in over the phone or online.  Please continue to check this page for updates. For updates, please ensure you are subscribed to receive emails from the Lymphoma Research Foundation

For LRF’s official statement on COVID-19 and LRF programs and events, please click here.

Virtual Lymphoma Rounds: Los Angeles – Save the Date

Los Angeles, CA

Date: Monday, June 8, 2020
Time: 6:30 PM – 8:30 PM PT

ACTIVITY CHAIRS

Ann Mohrbacher, MD
University of Southern California

Jasmine Zain, MD
City of Hope

This program is free for healthcare professionals; however, pre-registration is required. Registration information available soon.

Please note: Only representatives from supporting pharmaceutical companies are invited to register. If your company is interested in becoming a Lymphoma Rounds supporter please contact Sarah Quinlan, LRF, at squinlan@lymphoma.orgVirtual Exhibit opportunities are available.

Companies that have secured a national exhibit sponsorship for Lymphoma Rounds must still rsvp by emailing Sarah Quinlan (squinlan@lymphoma.org) at least one week before the program to confirm their attendance.

ABOUT THE PROGRAM
The Lymphoma Rounds program provides a forum for local practicing physicians from academic and community medical centers to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients. Physicians share best practices and learn the latest information on new therapies and advances in the management of lymphoma through interactive case studies presented by lymphoma experts in the local area.

At the conclusion of this educational activity, the participant should be better able to:

  • Summarize the latest developments in lymphoma diagnosis, treatment and management.
  • Apply best practices for treating lymphoma patients.
  • Inform patients about potential clinical trial opportunities.
  • Establish a network of health care professionals who work with lymphoma patients.

This program completes the 2019-20 Los Angeles Rounds series.

 

Los Angeles Lymphoma Rounds Steering Committee

Cedars-Sinai Medical Center
Noah Merin, MD, PhD
City of Hope
Jasmine Zain, MD
Harbor-UCLA Medical Center
Sarah Tomassetti, MD
Southern California Permanente Medical Group
Kathy Pan, MD
University of California, Irvine
Elizabeth Brem, MD
Lauren Pinter-Brown, MD, FACP (chair)
University of California, Los Angeles
Herbert Eradat, MD, MS
University of Southern California
Ann Mohrbacher, MD

Joint Providership Statement

This activity has been planned and implemented in accordance with the Accreditation Requirements and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and the Lymphoma Research Foundation.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Statement

The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit (s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsors
Lymphoma Research Foundation and the University of Nebraska Medical Center, Center for Continuing Education

This activity is supported by educational grants from:
Acrotech Biopharma, LLC, AstraZeneca, Celgene Corporation, Janssen Scientific Affairs, LLC and Pharmacyclics, LLC, an AbbVie Company, Novartis Pharmaceuticals Corporation, Seattle Genetics, Inc., TG Therapeutics, Inc. and Verastem, Inc.